NEW YORK (GenomeWeb News) – In the latter half of 2013, Bio-Rad Laboratories accrued $35 million in costs associated with its initial efforts to resolve investigations into violations of federal anti-bribery laws, the company said in its Form 10-K this week. The company had previously said that in 2010 it disclosed to the US Department of Justice and the US Securities and Exchange Commission that conduct by certain of its overseas operations may have violated the anti-bribery provisions of the US Foreign Corrupt Practices Act.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.

The New York Times editorial board weighs in on scientific research misconduct.

The European Commission says it won't take funds from the European Research Council's budget for its new European Fund for Strategic Investment.

The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.